#fact
- ABT-263→OSK 间隔的保守锚定原则 20260425183256000
- 零EV来源占比误差预算表 20260425181651000
- 皮肤中 senolytic→OSK 的最小实验蓝图 20260425181207000
- 来源占比误差会把零EV边界直接推翻 20260425181053000
- 渠道零EV门槛表（保守重算） 20260425180829000
- 部分重编程 go/no-go 判据与安全边界 20260425180607000
- 零EV边界应以来源混合区间而非单点成交率表达 20260425175436000
- 零EV 边界的来源混合重算公式 20260425175246000
- 顺序联合比较必须先锁组织与读出 20260425174929000
- senolytic→OSK 顺序联合的原始证据边界 20260425174632000
- 自噬轴候选应分为“独立干预、上游状态与 readout”三层 20260425174343000
- 成年哺乳动物自噬增强候选的审计结论 20260425174141000
- 自噬增强原始正例检索的噪音类型 20260425173833000
- 成年哺乳动物自噬增强正例的统一审计边界 20260425173655000
- TFEB-mediated autophagy can extend lifespan in middle-aged mice 20260425173437000
- 20人样本一页式决策器 20260425173357000
- 20人样本下的分段门槛决策表 20260425173312000
- 各渠道的零EV成交率门槛 20260425172711000
- 获客渠道的线索温度阶梯 20260425172527000
- 骨相关系统中的 senolytic→OSK 顺序实验仍未检出 20260425171453000
- 非糖尿病急性骨折/肌腱修复中的 senolytic 证据缺口 20260425171209000
- 急性骨/肌腱修复中的 senolytic 方向依赖组织与背景 20260425171003000
- senolytic 在非糖尿病急性神经损伤中可能促再生而非单向延迟修复 20260425170752000
- senolytic 对急性修复并非必然有害 20260425170413000
- 单一组织内 senescence 负担态与生态位态的可证伪判别框架 20260425165902000
- warm lead 原始记录的外部载体先于核验 20260425165018000
- 骨组织中 OSK 与 senolytic 的最小代理终点 20260425164755000
- Autophagy is a baseline-positive mammalian longevity node 20260425163912000
- 自噬轴第三条成年哺乳动物原始正例的审计边界 20260425163721000
- warm lead 的最低回复阈值由资格率与成交率共同决定 20260425163654000
- 间接自噬关联证据不应计入直接自噬增强正例 20260425162314000
- ER stress UPR not yet baseline-positive as a mammalian longevity node 20260425154643000
- Heat-shock/chaperone augmentation is not yet baseline-positive as a mammalian longevity node 20260425154317000
- Proteasome augmentation is not yet baseline-positive as a longevity node 20260425154052000
- Mitochondrial interventions have direct lifespan-endpoint positives, but evidence is heterogeneous 20260425153808000
- Autophagy enhancement is not yet baseline-positive like rapamycin/mTOR 20260425153601000
- Rapamycin is a baseline-positive specific node; autophagy and mitochondria are not automatically longevity candidates 20260425153226000
- mTOR/rapamycin 优先于泛化自噬/线粒体作为长寿候选 20260425152830000
- IL-11 的寿命/健康寿命效应大小与证据边界 20260425152333000
- IL-11 抑制的成年哺乳动物证据层级 20260425152029000
- IL-11 修复代价的直接成人哺乳动物原始反例仍未检出 20260425151726000
- Adult-mammal IL-11 inhibition: direct bone-homeostasis harm, fracture/wound evidence still missing 20260425151443000
- IL-11 longevity benefit must be decomposed into immune/inflammatory and tissue-tradeoff components 20260425150607000
- IL-11 currently ranks above other screened immune/inflammation axes because it has direct mammalian healthspan/lifespan evidence 20260425150330000
- 补体级联仍未跨过通用长寿瓶颈门槛 20260425150146000
- IL-1/MyD88 outranks TNF/IL-6 as an upstream screening candidate, but not as a universal bottleneck 20260425145846000
- Complement cascade remains a high-potential but not yet universal longevity bottleneck 20260425145530000
- TNF/IL-6 are low-priority control axes in longevity bottleneck screening 20260425145355000
- cGAS-STING is a strong but context-dependent aging node, not yet a universal longevity bottleneck 20260425145335000
- type I interferon / JAK-STAT is an upstream amplifier, not a default universal longevity bottleneck 20260425145224000
- Thymic source restoration is a strong immune upstream entry, but not yet a universal longevity bottleneck 20260425144604000
- TNF/IL-6 are context-specific inflammaging mediators, not universal longevity bottlenecks 20260425144110000
- cGAS-STING is an upstream inflammaging amplifier, but not yet a universal longevity bottleneck 20260425143829000
- NLRP3 is a strong aging node but still not clearly a universal longevity bottleneck 20260425143408000
- 资源撮合的杠杆属性：放大器优先，起手式谨慎 20260425143144000
- complement 轴是高潜力候选但尚非 universal longevity bottleneck 20260425143032000
- 交易要先覆盖波动与摩擦 20260425143008000
- 投资交易的可持续性取决于边际优势是否覆盖波动与摩擦 20260425142949000
- IL-11 longevity candidacy must be split by tissue-specific tradeoffs 20260425142558000
- 赚钱路径的通用排序：先现金流、后可复制业务、再资产/期权 20260425142251000
- IL-1 is a strong upstream hematopoietic inflammaging loop, but not yet a universal longevity bottleneck 20260425142133000
- 成年啮齿类骨折愈合中的 IL11/IL11RA1 直接因果证据仍未检出 20260425140608000
- IL-11 骨折愈合原始因果证据仍未检出 20260425140012000
- IL-11 inhibition: bone-homeostasis evidence is direct, fracture-healing evidence remains missing 20260425135719000
- Adult-mammal IL-11 inhibition has clear bone-homeostasis consequences, but direct fracture/wound inhibition evidence is sparse 20260425135357000
- IL-11 still needs a pleiotropy tradeoff audit before universal-bottleneck promotion 20260425134905000
- IL-6 trans-signaling is a plausible inflammaging axis, but not a universal longevity bottleneck 20260425134712000
- IgG/FcRn is a strong immune age-amplifying axis, but not yet a universal longevity bottleneck 20260425134301000
- IL-1 outranks TNF and type I IFN as an upstream immune loop, but still falls short of a universal longevity bottleneck 20260425133745000
- IL-11 is a strong candidate but not yet a universal bottleneck 20260425133514000
- IL-17 / Th17 is a context-dependent inflammaging axis, not a universal longevity bottleneck 20260425133233000
- IL-11 remains the current top immune/inflammation longevity candidate, but not yet a universal bottleneck 20260425132624000
- C1q brain aging mechanism is informative but still insufficient for universal longevity candidacy 20260425131714000
- IL-11 is currently the strongest immune/inflammation longevity candidate in the screening set 20260425131144000
- IgG is a strong age-amplifying node, but not yet a universal longevity bottleneck 20260425130909000
- Antibody / IgG accumulation is a strong age-amplifying node, but not yet a universal longevity bottleneck 20260425130643000
- trained immunity is a functional defense amplifier, not a higher-priority longevity bottleneck than thymic source restoration 20260425130412000
- IL-1 / emergency myelopoiesis is upstream of aged HSC bias, but not yet a universal longevity bottleneck 20260425125943000
- type I interferon / JAK-STAT chronic activation is strong but context-dependent, not yet a universal bottleneck 20260425125646000
- C1q is aging-associated but not yet a universal longevity bottleneck 20260425125313000
- IL-11 is a strong lifespan-positive inflammaging node, but still not yet a universal immune bottleneck 20260425124410000
- FGF21 不是通用免疫长寿瓶颈，而是局部胸腺 niche 入口 20260425123837000
- NLRP3 is context-dependent longevity-positive, not yet a universal bottleneck 20260425051109000
- 单组织寿命正例不足以把炎症轴抬升为通用长寿瓶颈 20260425050954000
- HSC/髓系偏置尚不能压过胸腺源恢复的免疫长寿排序 20260425050727000
- 局部语境决定抗衰老信号是否成立 20260425050544000
- Source-restoration immune entries outrank peripheral T-cell quality control when only the former has healthspan extension 20260425050521000
- Mature T-cell quality control usually ranks below thymic source restoration as a longevity entry 20260425050406000
- 免疫长寿入口的上游性排序：补给源 > 外周质量控制 > 局部 niche 维护 20260425050257000
- Peripheral T-cell quality control can reach frailty, but not yet lifespan 20260425050159000
- Peripheral T-cell quality control can reach frailty, while thymic regeneration remains mainly immune-readout level 20260425044850000
- T-cell Bcl-xL is a concrete peripheral quality-control example, but still not a validated universal longevity bottleneck 20260425044154000
- Peripheral lymph node niche repair is a lower-rank immune rejuvenation entry than thymic regeneration 20260425043703000
- Peripheral lymph node niche is a reversible immune entry, but not yet higher-leverage than thymic involution 20260425043458000
- Thymic involution remains the strongest reversible immune entry, but not yet a validated longevity bottleneck 20260425042531000
- IL-1 emergency myelopoiesis is upstream but not yet validated as a longevity bottleneck 20260425042245000
- Trained immunity is not yet a validated longevity bottleneck 20260425042105000
- Thymus regeneration improves immune readouts but not yet lifespan evidence 20260425041751000
- Immune rejuvenation can improve systemic aging phenotypes via thymic or peripheral routes 20260425041629000
- Immune interventions can improve systemic aging phenotypes, but not always via thymic regeneration 20260425041447000
- Immune longevity candidate ranking: thymic involution first, readouts later 20260425041227000
- Thymic involution can be experimentally reversed to restore naive T-cell output in aged mice 20260425040945000
- Netrin-1 可作为老化骨髓 niche 的可逆上游杠杆 20260425040329000
- Blood-aging candidate ranking: HSC exhaustion over CHIP; cell competition as framework 20260425040156000
- cell competition is a generic tissue-level quality-control framework 20260425040057000
- Bone marrow niche rejuvenation can restore aged HSC fitness 20260425035840000
- 年龄相关克隆现象优先视为读出而非总瓶颈 20260425035640000
- CHIP 更适合作为 HSC aging 的读出而非单一上游瓶颈 20260425035624000
- CDKN2A-OSK 在皮肤创面中的 FOSL1/迁移信号更应默认按间接效应解释 20260425035159000
- CDKN2A-OSK 在人皮肤创面中的直接效应与微环境间接效应应分层判断 20260425034935000
- FOSL1 不能被当成 CDKN2A-OSK 直接驱动角质形成细胞迁移的证据 20260425034652000
- CDKN2A-OSK 在人皮肤伤口边缘更像编辑炎症/应激状态，而非直接的增殖开关 20260425034427000
- 重编程效应要拆成炎症编辑与增殖激活两条轴 20260425034206000
- partial reprogramming 在人皮肤修复中更像炎症/应激状态编辑，而非增殖开关 20260425034137000
- partial reprogramming 在皮肤修复中更像炎症/应激状态编辑 20260425033952000
- human skin wound-healing roadmap cleanly separates acute-support and chronic-failure programs 20260425033600000
- 修复失败常是跨细胞协同失配 20260425033050000
- chronic wound failure programs clarify which senescence states are pathological 20260425033027000
- acute skin wound healing contains distinct senescent subpopulations with opposite effects 20260425032856000
- acute cutaneous wound healing is a clear example of context-dependent senescence 20260425032612000
- partial reprogramming can improve regeneration by remodeling the extrinsic niche 20260425032418000
- senolysis before OSK may remove a pro-reprogramming niche in some contexts 20260425032136000
- 同组织 senolytic 预处理后再做 OSK 的原始实验仍未检出 20260425031957000
- senolytic 预处理与 OSK 增效证据未检出 20260425031913000
- 体外与器官类系统中也未检出 senolytic→OSK 原始顺序实验 20260425031655000
- 另一单一组织中的 senolytic→OSK 顺序组合仍未检出 20260425031525000
- 顺序联合比单药 head-to-head 更有信息量 20260425030652000
- Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing 20260425030358000
- 皮肤 OSK vs ABT-263 参数对齐表（补全版） 20260425030211000
- 皮肤 OSK vs ABT-263 可执行参数表（反证版） 20260425025941000
- OSK vs ABT-263 的对齐/不对齐清单（皮肤场景） 20260425025615000
- Topical ABT-263 in aged mouse skin: original study and readouts 20260425025523000
- Targeted partial reprogramming of age-associated cell states: skin-relevant OSK parameters 20260425025310000
- OSK vs senolytic direct head-to-head remains sparse across tissues 20260425022737000
- 皮肤中 OSK vs ABT-263 的原始 head-to-head 未检到 20260425022429000
- 同组织头对头证据比并列正例稀缺 20260425021819000
- 统一比较组织的选择原则：皮肤是当前可用候选面板 20260425021710000
- 局部正例不能直接外推为长寿主路线代表性 20260425021446000
- 同一读出面板下比较长寿瓶颈候选的工程准则 20260425021221000
- 功能性与组织完整性读出：部分重编程验证的最小并列面板 20260425020502000
- 表观遗传主读出设计原则：组织特异DNAm时钟优先 20260425020313000
- Partial reprogramming 的优先干预模态选择原则 20260425020147000
- 表观遗传信息损失的可检验干预与读出方案 20260425015926000
- Epigenetic information loss as a testable longevity bottleneck 20260425015600000
- 三态判别协议的压力测试结果 20260425015339000
- 旧前缀+下一前缀联合生存刻画中性（small-case） 20260425014335000
- 旧前缀可替代嵌入不足以判别中性 20260425013950000
- 单一局部特征通常只能给出必要条件 20260425013436000
- 单侧交换位置可压缩为局部窗口 20260425010941000
- 交换不依赖右侧的充分条件 20260425005858000
- 左侧一次相邻交换的切分判定复用模板 20260425005439000
- Iter-4360dd15-0186-fact-left-prefix-consumption-cut 20260425002431000
- Iter-4360dd15-0178-fact-support-contained-window-decidable-audit 20260424234738000
- Iter-4360dd15-0174-fact-exhaustive-reachability-audit 20260424233953000
- Iter-4360dd15-0173-fact-support-contained-boundary-consistency 20260424233814000
- Iter-4360dd15-0172-fact-accept-support-contained-boundary-consistency 20260424233727000
- Iter-4360dd15-0171-fact-minimal-counterexample-support-contained-window 20260424233529000
- Iter-4360dd15-0166-fact-minimal-insertion-reorder-counterexample 20260424232532000
- Iter-4360dd15-0165-method-content-subsequence-local-insertion 20260424232430000
- 重写判定要分层 20260424231903000
- 重写判定要用二层信号 20260424231655000
- 重写判定必须分层 20260424231556000
- Iter-4360dd15-0160-method-pmc4083033-rewrite-v2 20260424231537000
- Iter-4360dd15-0159-lesson-rewrite-threshold-failure 20260424231322000
- Iter-4360dd15-0158-method-pmc4083033-sentence-rewrite-template 20260424231132000
- Iter-4360dd15-0157-fact-pmc4083033-word-diff 20260424231031000
- Iter-4360dd15-0156-fact-pmc4083033-xml-offsets 20260424230924000
- Iter-4360dd15-0155-fact-pmc4083033-xml-coordinates 20260424230807000
- Iter-4360dd15-0154-fact-pmc4083033-tokenization-robustness 20260424230648000
- Iter-4360dd15-0153-fact-pmc4083033-direct-xml-diff 20260424230526000
- Iter-4360dd15-0152-fact-pmc4083033-diff-type 20260424230323000
- BOLERO-2 erratum abstract verbatim chain 20260424222829000
- BOLERO-2 erratum: full corrected abstract sentence 20260424222041000
- BOLERO-2 erratum: abstract correction scope corroborated from source text 20260424221844000
- BOLERO-2 erratum: exact deleted abstract span 20260424221738000
- BOLERO-2 PMID 22149876 vs PMC4713958: verbatim abstract diff 20260424221644000
- BOLERO-2 erratum: original abstract sentence vs corrected sentence 20260424221539000
- BOLERO-2 erratum verbatim boundary proof 20260424221251000
- BOLERO-2 abstract erratum verbatim comparison 20260424221118000
- BOLERO-2 erratum exact abstract sentence and boundary of correction 20260424221021000
- BOLERO-2 erratum corrected abstract sentence 20260424220843000
- BOLERO-2 abstract should cite erratum-corrected subgroup wording 20260424220656000
- BOLERO-2 erratum scope: subgroup wording only, PFS numerics unchanged 20260424220522000
- BOLERO-2 erratum does not change abstract investigator-assessed PFS sentence or bibliographic metadata 20260424220413000
- BOLERO-2 PMCID and abstract PFS sentence directly verified from PMC 20260424220204000
- BOLERO-2 PMID PMCID DOI confirmed from Europe PMC and PMC 20260424220045000
- BOLERO-2 主文数值与 PMID/DOI 的直接抽取（Springer OA + NCBI export） 20260424215916000
- BOLERO-2 主要终点具体结果数值（Springer OA） 20260424215736000
- BOLERO-2 可访问非-NEJM 设计/终点证据已补齐 20260424215252000
- BOLERO-2 PMID 22149876 的可访问非-NEJM 设计/终点复核 20260424215102000
- BOLERO-2 PMID 22149876 的第二独立复核来源与 primary endpoint 20260424214827000
- BOLERO-2 原始主报告 PMID 22149876 与 primary endpoint PFS 20260424214522000
- PMID 22149876 is the original BOLERO-2 phase 3 primary report, not 24267730 20260424214401000
- PMID 24267730 is a subgroup analysis, not the first original human trial 20260424214147000
- Iter-4360dd15-0106-four-candidate-audit 20260424213752000
- Iter-4360dd15-0104-three-remaining-candidates-are-not-original-first-reports 20260424213638000
- Iter-4360dd15-0103-EuropePMC-38310895-reference-parser-and-candidate-shortlist 20260424213315000
- Iter-4360dd15-0100-human-trial-vs-non-original-screening-of-38310895-references 20260424212530000
- Iter-4360dd15-0098-EuropePMC-extract-human-trial-PMIDs 20260424212055000
- PMID 22367193 is cardiac-repolarization safety, not longevity evidence 20260424210833000
- PMID 24691032 is muscle-protein-synthesis endpoint, not longevity evidence 20260424210355000
- PMID 22115710 is phase I ocular safety study, not longevity evidence 20260424210145000
- PMID 29408453 is feasibility/safety pilot, not direct longevity evidence 20260424210012000
- PMID 33977284 is RTI incidence endpoint, not direct longevity evidence 20260424204839000
- PMID 25540326 is immune-response endpoint, not longevity evidence 20260424204718000
- PMID 27883166 is a pilot safety feasibility trial not direct longevity evidence 20260424204543000
- PEARL trial is not direct longevity evidence 20260424203525000
- Iter-4360dd15-0078-two-pmid-evidence-verification 20260424203242000
- Iter-4360dd15-0077-unified-longevity-classification-four-pmids 20260424203137000
- Iter-4360dd15-0075-abstract-field-extraction-two-pmids 20260424202951000
- Iter-4360dd15-0069-standardized-audit-table-two-trials 20260424201621000
- Iter-4360dd15-0068-abstract-endpoint-extraction 20260424201407000
- Iter-4360dd15-0067-abstract-endpoints-aging-criteria 20260424201141000
- Iter-4360dd15-0066-TierA-abstracts-and-endpoints-for-aging-criteria 20260424200925000
- Iter-4360dd15-0065-minimal-relevance-decision-rules-for-retained-mtor-trials 20260424200748000
- Iter-4360dd15-0064-relevance-tiering-10-pmids 20260424200602000
- Iter-4360dd15-0063-10-pmid-audit-table 20260424200432000
- Iter-4360dd15-0062-pubmed-title-verification-10-pmids 20260424200328000
- Iter-4360dd15-0061-candidate-audit-10-remaining-pmids 20260424200221000
- PMID 38310895 is a review, not a primary trial 20260424200109000
- PMID 35040506 longitudinal analysis is embedded in primary trial 20260424195939000
- Iter-4360dd15-0058-longevity-evidence-proximity-tagging 20260424195827000
- Iter-4360dd15-0057-study-design-taxonomy-for-retained-trials 20260424195711000
- Iter-4360dd15-0056-pubmed-boundary-confirmation 20260424195548000
- Iter-4360dd15-0053-final-audit-14-candidates 20260424194939000
- Iter-4360dd15-0052-rapamycin-older-cohort-pmid-mapping 20260424194711000
- Iter-4360dd15-0048-crossref-trialish-candidate-extraction 20260424194106000
- PMID 38310895 access topology verified 20260424193545000
- Iter-4360dd15-0042-crossref-family-collapse-10-families 20260424192619000
- Iter-4360dd15-0040-crossref-trialish-family-taxonomy 20260424192051000
- Iter-4360dd15-0039-crossref-candidate-family-critique 20260424191812000
- Iter-4360dd15-0038-crossref-human-trial-filter-method 20260424191618000
- Iter-4360dd15-0030-vu-research-portal-entry-without-direct-pdf-link 20260424185400000
- 2024 rapamycin systematic review: abstract-level constraints and what remains missing 20260424175824000
- Added included ADPKD rapalog trial CRAD001ADE12 and its body-weight endpoint 20260424174657000
- Rapamycin human trials: completed studies table from PMC review 20260424174352000
- Rapamycin human trials: extracted endpoints and outcomes from the 2024 systematic review review pass 1 20260424173529000
- Human longevity interventions evidence maturity matrix 2026-04-25 20260424173237000
- Prime-100 mod6 minimal transition table verified 20260424171809000
- Prime-100 gap motif compressed verified 20260424171706000
- Prime-100 pattern gaps verified 20260424171335000
- Prime-100 pattern last digit verified 20260424171237000
- Prime-100 pattern mod 6 verified 20260424171150000